



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

November 24, 2021

David Mehalick
President and Chief Executive Officer
Coepit Therapeutics, Inc.
105 Bradford Rd., Suite 420
Wexford, Pennsylvania 15090

Re: Coepit Therapeutics, Inc.
Offering Statement on Form 1-A
Filed November 18, 2021
File No. 024-11719

Dear Mr. Mehalick:

This is to advise you that we do not intend to review your offering statement.

We will consider qualifying your offering statement at your request. If a participant in your offering is required to clear its compensation arrangements with FINRA, please have FINRA advise us that it has no objections to the compensation arrangements prior to qualification.

We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. We also remind you that, following qualification of your Form 1-A, Rule 257 of Regulation A requires you to file periodic and current reports, including a Form 1-K which will be due within 120 calendar days after the end of the fiscal year covered by the report.

Please contact Joshua Gorsky at (202) 551-7836 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences